Posted by Michael Wonder on 12 Jul 2022
Hansa Biopharma announces first patient treated in the post-authorisation efficacy study of Idefirix (imlifidase) in highly sensitised kidney transplant patients
11 July 2022 - The study is an obligation under the conditional marketing authorisation for Idefirix granted by the EMA in August 2020.
Hansa Biopharma announces today that the first patient has been treated in the PAES for Idefirix as a desensitisation treatment for highly sensitised people undergoing a kidney transplant.
